Vindesine

An effective agent in the treatment of non-small cell lung cancer

B. E. Furnas, S. D. Williams, Lawrence Einhorn, M. A. Cobleigh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A dose of 3-4 mg/m2 of vindesine (DVA) was given by iv push weekly to 33 patients with non-small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable patients had a performance status > 50% and measurable disease, and received at least two consecutive weekly doses of DVA. Standard response criteria were used. Among 15 patients with squamous cell carcinoma there were four partial responses and one complete response; three of eight patients with adenocarcinoma had partial responses. The overall response rate was 28% (eight responses among 29 patients). Myelosuppression was moderate, but two patients were hospitalized for granulocytopenic infections. The most common dose-limiting side effects were due to neurotoxicity. Four responding patients had treatment stopped because of neurotoxic reactions. DVA appears to be among the most active drugs in non-small cell lung cancer, but improved dose schedules that reduce neurotoxicity would be highly desirable.

Original languageEnglish
Pages (from-to)1709-1711
Number of pages3
JournalCancer Treatment Reports
Volume66
Issue number9
StatePublished - 1982

Fingerprint

Vindesine
Non-Small Cell Lung Carcinoma
Therapeutics
Squamous Cell Carcinoma
Appointments and Schedules
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Furnas, B. E., Williams, S. D., Einhorn, L., & Cobleigh, M. A. (1982). Vindesine: An effective agent in the treatment of non-small cell lung cancer. Cancer Treatment Reports, 66(9), 1709-1711.

Vindesine : An effective agent in the treatment of non-small cell lung cancer. / Furnas, B. E.; Williams, S. D.; Einhorn, Lawrence; Cobleigh, M. A.

In: Cancer Treatment Reports, Vol. 66, No. 9, 1982, p. 1709-1711.

Research output: Contribution to journalArticle

Furnas, BE, Williams, SD, Einhorn, L & Cobleigh, MA 1982, 'Vindesine: An effective agent in the treatment of non-small cell lung cancer', Cancer Treatment Reports, vol. 66, no. 9, pp. 1709-1711.
Furnas, B. E. ; Williams, S. D. ; Einhorn, Lawrence ; Cobleigh, M. A. / Vindesine : An effective agent in the treatment of non-small cell lung cancer. In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 9. pp. 1709-1711.
@article{17208f311ae044538e1fb37f549cdf08,
title = "Vindesine: An effective agent in the treatment of non-small cell lung cancer",
abstract = "A dose of 3-4 mg/m2 of vindesine (DVA) was given by iv push weekly to 33 patients with non-small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable patients had a performance status > 50{\%} and measurable disease, and received at least two consecutive weekly doses of DVA. Standard response criteria were used. Among 15 patients with squamous cell carcinoma there were four partial responses and one complete response; three of eight patients with adenocarcinoma had partial responses. The overall response rate was 28{\%} (eight responses among 29 patients). Myelosuppression was moderate, but two patients were hospitalized for granulocytopenic infections. The most common dose-limiting side effects were due to neurotoxicity. Four responding patients had treatment stopped because of neurotoxic reactions. DVA appears to be among the most active drugs in non-small cell lung cancer, but improved dose schedules that reduce neurotoxicity would be highly desirable.",
author = "Furnas, {B. E.} and Williams, {S. D.} and Lawrence Einhorn and Cobleigh, {M. A.}",
year = "1982",
language = "English",
volume = "66",
pages = "1709--1711",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Vindesine

T2 - An effective agent in the treatment of non-small cell lung cancer

AU - Furnas, B. E.

AU - Williams, S. D.

AU - Einhorn, Lawrence

AU - Cobleigh, M. A.

PY - 1982

Y1 - 1982

N2 - A dose of 3-4 mg/m2 of vindesine (DVA) was given by iv push weekly to 33 patients with non-small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable patients had a performance status > 50% and measurable disease, and received at least two consecutive weekly doses of DVA. Standard response criteria were used. Among 15 patients with squamous cell carcinoma there were four partial responses and one complete response; three of eight patients with adenocarcinoma had partial responses. The overall response rate was 28% (eight responses among 29 patients). Myelosuppression was moderate, but two patients were hospitalized for granulocytopenic infections. The most common dose-limiting side effects were due to neurotoxicity. Four responding patients had treatment stopped because of neurotoxic reactions. DVA appears to be among the most active drugs in non-small cell lung cancer, but improved dose schedules that reduce neurotoxicity would be highly desirable.

AB - A dose of 3-4 mg/m2 of vindesine (DVA) was given by iv push weekly to 33 patients with non-small cell lung cancer. Twenty-nine patients were evaluable for response. All evaluable patients had a performance status > 50% and measurable disease, and received at least two consecutive weekly doses of DVA. Standard response criteria were used. Among 15 patients with squamous cell carcinoma there were four partial responses and one complete response; three of eight patients with adenocarcinoma had partial responses. The overall response rate was 28% (eight responses among 29 patients). Myelosuppression was moderate, but two patients were hospitalized for granulocytopenic infections. The most common dose-limiting side effects were due to neurotoxicity. Four responding patients had treatment stopped because of neurotoxic reactions. DVA appears to be among the most active drugs in non-small cell lung cancer, but improved dose schedules that reduce neurotoxicity would be highly desirable.

UR - http://www.scopus.com/inward/record.url?scp=0019934202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019934202&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 1709

EP - 1711

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -